论文部分内容阅读
目的观察唑来膦酸联合化疗和单用化疗治疗恶性肿瘤骨转移的疗效与毒性。方法 45例骨转移患者随机分为联合治疗组和单纯化疗组,治疗组(23例)接受唑来膦酸联合化疗,对照组(22例)单用化疗,两组同病种化疗方案相同。结果治疗组和对照组疼痛总缓解率分别为82.6%和54.5%,体力状况总改善率分别为69.6%和31.8%,骨病灶总控制率分别为55.2%和22.7%%,差异均有统计学意义(P<0.05),而毒副反应差异无统计学意义(P>0.05)。结论唑来膦酸联合化疗治疗恶性肿瘤骨转移疗效优于单用化疗,毒副反应无差异,值得临床进一步推广应用。
Objective To observe the efficacy and toxicity of zoledronic acid combined with chemotherapy and chemotherapy alone in the treatment of bone metastases of malignant tumors. Methods Forty-five patients with bone metastases were randomly divided into combined therapy group and chemotherapy alone group. The treatment group (23 patients) received zoledronic acid combined with chemotherapy and the control group (22 patients) received chemotherapy alone. The two groups were the same as the chemotherapy regimens. Results The total pain relief rates of the treatment group and the control group were 82.6% and 54.5%, respectively. The total improvement rates of physical condition were 69.6% and 31.8% respectively. The total control rates of bone lesions were 55.2% and 22.7% respectively, with statistical differences Significance (P <0.05), but no significant difference in the side effects (P> 0.05). Conclusion Zoledronic acid combined with chemotherapy is superior to chemotherapy alone in the treatment of malignant bone metastases, with no difference in toxic and side effects. It is worth further clinical application.